ACTRN12624000030572招募中Unknown
Proof of concept trial: Investigating the user experience of patient empowered monitoring for patients with high-risk of readmission with heart failure and chronic kidney disease
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Adult patients (aged 18 years and over)
- •- Able to give informed consent for medical decisions.
- •- Have both heart failure and chronic kidney disease (stage 3-5)
- •- Meet eligibility criteria for Health-Links program (hospital program for patients with chronic health needs at high risk of readmission noting most patients with heart failure and kidney disease would meet criteria).
- •- Have an Apple phone device.
排除标准
- •-Participants who are unable to use a Smart phone / watch (or have someone who can assist them)
- •-Participants who do not speak basic English (application currently in English).
- •Note: study investigators acknowledge the exclusion criteria leads to a narrow and unique population that is not a representative sample. A future trial based on learnings and optimisation is planned that will broaden the inclusion/exclusion criteria to a range of consumer devices and common languages.
研究者
相似试验
进行中（未招募）
1 期
Pilot trial to test the treatment effects of Valerian extract (Euvegal®) and Lavender oil (Lasea®) in patients suffering from inability to fall or stay asleeponorganic insomnia according to ICD 10 with the code F51.0MedDRA version: 20.0 Level: LLT Classification code 10022438 Term: Insomnia (non-organic) System Organ Class: 100000014712EUCTR2015-003265-29-DEDr. Willmar Schwabe GmbH & Co. KG30
进行中（未招募）
不适用
A Double-blind, Proof of Concept Trial of the Use of Pegvisomant to Reduce UrinaryAlbumin Excretion in Type 1 and Type 2 Diabetic Patients Treated with Angiotensin Convertase Inhibitors/Angiotensin Receptor Blockers, with Persistent Albuminuria - N/ADiabetic nephropathy DN (Diabetes mellitus (DM) type I and type II with renal manifestations).MedDRA classification code : 10061835, 10045236 and 10045250 (Version 7.0, Level LLT)EUCTR2004-001190-25-LTPfizer Ltd180
进行中（未招募）
不适用
A Double-blind, Proof of Concept Trial of the use of Pegvisomant to Reduce UrinaryAlbumin excretion in Type 1 and Type 2 Diabetic Patients treated with Angiotensin Convertase Inhibitors/Angiotensin receptor blockers, with persistent Albuminuria. - N/ADiabetic nephropathy DN (Diabetes mellitus (DM) type I and type II with renal manifestations).MedDRA classification code : 10061835, 10045236 and 10045250 (Version 7.0, Level LLT)EUCTR2004-001190-25-DEPfizer Pharma GmbH180
进行中（未招募）
不适用
A Double-blind, Proof of Concept Trial of the use of Pegvisomant to Reduce UrinaryAlbumin excretion in Type 1 and Type 2 Diabetic Patients treated with Angiotensin Convertase Inhibitors/Angiotensin receptor blockers, with persistent Albuminuria. - N/AEUCTR2004-001190-25-CZPfizer Ltd.180
进行中（未招募）
1 期
A Double-blind, Proof of Concept Trial of the use of Pegvisomant to Reduce Urinary Albumin excretion in Type 1 and Type 2 Diabetic Patients treated with Angiotensin Convertase Inhibitors/Angiotensin receptor blockers, with persistent Albuminuria. - N/AEUCTR2004-001190-25-GBPfizer Ltd180